留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

双氢青蒿素抗癌药理作用机制的研究进展

周许薇,  谭蔚锋,  解方园,  辛宝,  陈俊

downloadPDF
文章导航 > 药学实践与服务  > 2019 >  37(3): 206-211,278
周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
shu
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
shu

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003
  • 1.

    海军军医大学附属东方肝胆外科医院 药材科, 上海 200438

  • 2.

    海军军医大学附属东方肝胆外科医院 胆道四科, 上海 200438

Research progress on anti-tumor mechanisms of dihydroartemisinin

  • 1.

    Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital Affiliated to Naval Medical University, Shanghai 200438, China

  • 2.

    Department of Biliary Tract Surgery(Ⅳ), Eastern Hepatobiliary Surgery Hospital Affiliated to Naval Medical University, Shanghai 200438, China

  • 摘要: 双氢青蒿素是青蒿素的一种重要衍生物，是我国自行研发的抗疟新药。近年来，人们发现双氢青蒿素不但具有抗疟活性，而且具有良好的抗肿瘤效果，被认为是前景良好的抗肿瘤药。因此，综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展，主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。
    Abstract: Dihydroartemisinin(DHA),an important artemisinin derivative,is one of new anti-malarial medicines developed by Chinese scientists.In recent years,it was reported that DHA is a promising anti-cancer medicine besides its extraordinary antimalarial activities.This article overviews the mechanisms,targets and signaling pathways of DHA based on the recent studies published in English and Chinese literatures.Specifically,this article covers some important topics,such as apoptosis,endoplasmic reticulum stress,the growth,proliferation and invasion of cancer cells,multidrug resistance and oxidative damage,in order to provide a better understanding to the anti-cancer effects of DHA and information for new drug development and design.
  • [1] WONG Y K,XU C,KALESH K A,et al.Artemisinin as an anticancer drug:recent advances in target profiling and mechanisms of action[J].Med Res Rev,2017,37(6):1492-1517.
    [2] 郭宗儒.青蒿素类抗疟药的研制[J].药学学报,2016,51(1):157-164.
    [3] LU J J,MENG L H,SHANKAVARAM U T,et al.Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells[J].Biochem Pharmacol,2010,80(1):22-30.
    [4] LIANG S,SUN K,WANG Y,et al.Role of Cyt-C/caspases-9,3,Bax/Bcl-2 and the FAS death receptor pathway in apoptosis induced by zinc oxide nanoparticles in human aortic endothelial cells and the protective effect by alpha-lipoic acid[J].Chem Biol Interact,2016,258:40-51.
    [5] HE Q,SHI J,SHEN X L,et al.Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells[J].Cancer Biol Ther,2010,9(10):819-824.
    [6] KONG R,JIA G,CHENG Z X,et al.Correction:dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5[J].Plos ONE,2012,7(5):e37222.
    [7] LI Y W,ZHANG W,XU N,et al.Dihydroartemisinin inhibits proliferation of pancreatic cancer JF-305 cells by regulating expression of apoptosis related proteins and production of reactive oxygen species[J].Zhongguo Zhong Yao Za Zhi,2017,42(15):3026-3030.
    [8] ZUO Z J,WANG S T,JIANG L X,et al.Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study[J].Zhongguo Zhong XI Yi Jie He Za Zhi,2014,34(10):1220-1224.
    [9] LU M,SUN L,ZHOU J,et al.Dihydroartemisinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticulum calcium ATPase activity in colorectal cancer[J].Cell Biochem Biophys,2015,73(1):137-145.
    [10] QIN G,ZHAO C,ZHANG L,et al.Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells[J].Apoptosis,2015,20(8):1072-1086.
    [11] LIAO K,LI J,WANG Z.Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells[J].Int J Clin Exp Pathol,2014,7(12):8684.
    [12] FASANO E,SERINI S,PICCIONI E,et al.DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines[J].Biochim Biophys Acta,2012,1822(11):1762-1772.
    [13] CHEN S S,HU W,WANG Z,et al.p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy[J].Cancer Biol Ther,2015,16(5):770-779.
    [14] CHEN M,CHEN T S,LU Y Y,et al.Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells[J].Pathol Oncol Res,2012,18(4):809-816.
    [15] ZHANG C,SYED T W,LIU R,et al.Role of endoplasmic reticulum stress,autophagy,and inflammation in cardiovascular disease[J].Front Cardiovasc Med,2017,4:29.
    [16] DU X X,LI Y J,WU C L,et al.Initiation of apoptosis,cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin[J].Biomed Pharmac,2013,67(5):417-424.
    [17] MARCINIAK S J,RON D.Endoplasmic reticulum stress signaling in disease[J].Physiol Rev,2006,86(4):1133-1149.
    [18] SCHRÖDER M.Endoplasmic reticulum stress responses[J].Cell Mol Life Sci,2008,65(6):862-894.
    [19] WANG M,KAUFMAN R J.Protein misfolding in the endoplasmic reticulum as a conduit to human disease[J].Nature,2016,529(7586):326-335.
    [20] HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
    [21] INGHAM M,SCHWARTZ G K.Biology of neoplasia:cell-cycle therapeutics come of age[J].J Clin Oncol,2017,35(25):2949-2959.
    [22] MAGENTA D,SANGIOVANNI E,BASILICO N,et al.Inhibition of metalloproteinase-9 secretion and gene expression by artemisinin derivatives[J].Acta Trop,2014,140:77-83.
    [23] LIN R,ZHANG Z,CHEN L,et al.Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells[J].Cancer Lett,2016,381(1):165-175.
    [24] TONG Y,LIU Y,ZHENG H,et al.Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling[J].Oncotarget,2016,7(21):31413-31428.
    [25] MI Y,GENG G,ZOU Z,et al.Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J].PloS ONE,2015,10(3):e0120426.
    [26] ALASEEM A,ALHAZZANI K,Dondapati P,et al.Matrix metalloproteinases:a challenging paradigm of cancer management[J].Semin Cancer Biol,2017,Epub.
    [27] SHAO Y Y,ZHANG T L,WU L X,et al.AKT Axis,miR-21,and RECK play pivotal roles in dihydroartemisinin killing malignant glioma cells[J].Int J Mol Sci,2017,18(2):350.
    [28] HWANG Y P,YUN H J,KIM H G,et al.Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms[J].Biochem Pharmacol,2010,79(12):1714-1726.
    [29] HU C J,ZHOU L,CAI Y.Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2[J].Cancer Biol Ther,2014,15(3):279-288.
    [30] CHEN J,CHEN X,WANG F,et al.Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway[J].Neurol Sci,2015,36(3):435-440.
    [31] WANG S J,SUN B,CHENG Z X,et al.Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway[J].Cancer Chemother Pharmacol,2011,68(6):1421.
    [32] PILATI P,NITTI D,MOCELLIN S.Cancer resistance to type Ⅱ topoisomerase inhibitors[J].Curr Med Chem,2012,19(23):3900-3906.
    [33] WIJDEVEN R H,PANG B,ASSARAF Y G,et al.Old drugs,novel ways out:Drug resistance toward cytotoxic chemotherapeutics[J].Drug Resist Updat,2016,28:65-81.
    [34] ONTIKATZE T,RUDNER J,HANDRICK R,et al.Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells[J].Front Oncol,2014,4:116.
    [35] CARO J T,MARíN L M,IAZBIK M C,et al.Markers of iron metabolism in retired racing greyhounds with and without osteosarcoma[J].Vet Clin Pathol,2013,42(3):360-363.
    [36] JIA L,SONG Q,ZHOU C,et al.Dihydroartemisinin as a putative STAT3 inhibitor,suppresses the growth of head and neck squamous cell carcinoma by targeting Jak2/STAT3 signaling[J].PloS ONE,2016,11(1):e0147157.
    [37] CAO L,DUANMU W,YIN Y,et al.Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3[J].Pharmazie,2014,69(10):752-758.
  • [1] 方宇昕, 李育, 刘宝姝, 董国强.  线性泛素连接酶复合体与去线性泛素化酶在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(9): 534-539. doi: 10.12206/j.issn.2097-2024.202307045
    [2] 高习清, 卢光照, 鲁莹, 邹豪.  活性氧自由基响应型脂质体在抗肿瘤研究中的应用进展 . 药学实践与服务, 2023, 41(1): 14-17. doi: 10.12206/j.issn.2097-2024.202105086
    [3] 王智聪, 谢彬, 袁星, 徐希科, 柳润辉.  基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制 . 药学实践与服务, 2023, 41(5): 296-301. doi: 10.12206/j.issn.2097-2024.202112001
    [4] 黄晴, 施春燕.  基于网络药理学研究白芍治疗肝纤维化的作用机制 . 药学实践与服务, 2023, 41(8): 485-491. doi: 10.12206/j.issn.2097-2024.202208040
    [5] 谢彬, 袁星, 徐希科, 柳润辉.  中药复方抗动脉粥样硬化作用机制的研究进展 . 药学实践与服务, 2021, 39(4): 295-298, 304. doi: 10.12206/j.issn.1006-0111.202103001
    [6] 丁佳宁, 马进原, 朱全刚.  长链非编码RNA人母系表达基因3在肿瘤发生中作用的研究进展 . 药学实践与服务, 2019, 37(5): 390-393,421. doi: 10.3969/j.issn.1006-0111.2019.05.002
    [7] 陈自强, 张玮, 李玉平, 王晓宇.  纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展 . 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
    [8] 王欢, 马志强, 杨峰.  用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展 . 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
    [9] 赵娜, 高峰, 刘彬, 朴贤美.  苄基四氢异喹啉类生物碱的药理作用及其研究进展 . 药学实践与服务, 2015, 33(4): 313-315,323. doi: 10.3969/j.issn.1006-0111.2015.04.006
    [10] 武善超, 盛春泉, 张万年.  来源于天然产物的抗肿瘤先导结构研究进展 . 药学实践与服务, 2014, 32(5): 337-341,371. doi: 10.3969/j.issn.1006-0111.2014.05.005
    [11] 牛筛龙, 孙富增, 张兴耐.  秦艽总环烯醚萜苷的抗炎作用及其机制 . 药学实践与服务, 2013, 31(3): 198-200. doi: 10.3969/j.issn.1006-0111.2013.03.010
    [12] 赵心彬, 倪敏, 陶霞.  他汀类药物多效药理作用及其机制研究进展 . 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005
    [13] 路明珠, 张治强, 伊佳, 陈万生, 侯忠海, 李铁军.  知母皂苷B-Ⅱ抗抑郁作用及其机制研究 . 药学实践与服务, 2010, 28(4): 283-287.
    [14] 侯雪梅, 崔黎丽, 李国栋, 李卫华.  抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
    [15] 黄宝康, 郑汉臣, 秦路平.  缬草属植物的镇静催眠作用及机制 . 药学实践与服务, 2007, (3): 134-136,142.
    [16] 丁力, 丁家崇, 郭葆玉.  抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
    [17] 庞晓军, 黄军章, 刘国勇, 李香乐.  肿瘤基因治疗研究进展 . 药学实践与服务, 2006, (1): 4-6.
    [18] 王彦, 刁亚英, 姜远英.  ABC转运蛋白与肿瘤多药耐药 . 药学实践与服务, 2003, (1): 28-31.
    [19] 肖文中, 詹利之, 张美义, 林燕芳.  三波长分光光度法测定复方双氢青蒿素片中双氢青蒿素的含量 . 药学实践与服务, 2003, (2): 92-94.
    [20] 范开华, 刘子文, 夏俊.  血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  4609
  • HTML全文浏览量:  825
  • PDF下载量:  415
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-28
  • 修回日期:  2019-01-25

双氢青蒿素抗癌药理作用机制的研究进展

doi: 10.3969/j.issn.1006-0111.2019.03.003
  • 1. 海军军医大学附属东方肝胆外科医院 药材科, 上海 200438
  • 2. 海军军医大学附属东方肝胆外科医院 胆道四科, 上海 200438
  • 收稿日期: 2018-09-28
  • 修回日期: 2019-01-25

摘要: 双氢青蒿素是青蒿素的一种重要衍生物，是我国自行研发的抗疟新药。近年来，人们发现双氢青蒿素不但具有抗疟活性，而且具有良好的抗肿瘤效果，被认为是前景良好的抗肿瘤药。因此，综述目前双氢青蒿素抗肿瘤作用发生机制、靶点和通路的研究进展，主要包括癌细胞凋亡、内质网应激、癌细胞生长增殖、侵袭转移、肿瘤多药耐药以及细胞氧化损伤等方面。为抗肿瘤的基础研究、新药物研发以及药物设计提供参考和依据。

English Abstract

周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
引用本文: 周许薇, 谭蔚锋, 解方园, 辛宝, 陈俊. 双氢青蒿素抗癌药理作用机制的研究进展[J]. 药学实践与服务, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
shu
ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
Citation: ZHOU Xuwei, TAN Weifeng, XIE Fangyuan, XIN Bao, CHEN Jun. Research progress on anti-tumor mechanisms of dihydroartemisinin[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(3): 206-211,278. doi: 10.3969/j.issn.1006-0111.2019.03.003
shu

    全文HTML

参考文献 (37)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计